Ameriprise
PLX icon

Ameriprise’s Protalix BioTherapeutics PLX Stock Holding History

Ameriprise’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3
Closed – – 4220
2014
Q3 		$0 Hold
3
– – ﹤0.01% 5870
2014
Q2 		$0 Hold
3
– – ﹤0.01% 5636
2014
Q1 		$0 Hold
3
– – ﹤0.01% 5377
2013
Q4 		$0 Hold
3
– – ﹤0.01% 5366
2013
Q3 		$0 Hold
3
– – ﹤0.01% 5657
2013
Q2 		$0 Buy
+3
New +$159 ﹤0.01% 5569

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Ameriprise's PLX Position: Q4 2014 in Review

Ameriprise sold out of Protalix BioTherapeutics (PLX) in Q4 2014, closing a stake of 3 shares.

Ameriprise first reported a position in PLX in Q2 2013 and held it in 6 quarters. The position peaked at $0 in Q3 2014. 44 funds tracked by Wall St. Rank hold PLX as of Q4 2014.

  • Ameriprise reported no remaining Protalix BioTherapeutics position as of Q4 2014 after selling out during the quarter.
  • Ameriprise sold 3 Protalix BioTherapeutics shares in Q4 2014.
  • Ameriprise first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 6 quarters.
  • Ameriprise's Protalix BioTherapeutics position peaked at $0 in Q3 2014.
  • 44 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2014.

Based on Ameriprise's 13F filing for Q4 2014, filed 13 Feb 2015.